AdjuTec Pharma

Executive Summary

AdjuTec Pharma AS is a Norwegian biotech startup focused on combating antimicrobial resistance (AMR) by developing novel β-lactamase inhibitors (BLIs). These inhibitors are designed to inactivate bacterial resistance enzymes, thereby restoring the efficacy of existing broad-spectrum antibiotics against multidrug-resistant infections. The company's mission addresses a critical global health threat, as AMR renders traditional antibiotics increasingly ineffective. AdjuTec's technology platform also encompasses antibody-based therapies and vaccines, broadening its potential impact. Founded in 2015 and headquartered in Oslo, the company operates in the preclinical stage with a strong scientific foundation but limited public disclosures. Its proprietary BLIs could offer a cost-effective solution to extend the lifespan of current antibiotics, targeting serious hospital-acquired and community-acquired infections. While still early-stage, AdjuTec's approach has the potential to become a key component in the fight against AMR, pending successful development and partnerships.

Upcoming Catalysts (preview)

• 2026Preclinical Proof-of-Concept Data for Lead BLI Candidate45% success
• 2026-2027Series A Funding Round Closing60% success
• TBDResearch Collaboration or Licensing Deal with Major Pharma30% success